M Meyerson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
    Xiaojun Zhao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:5561-70. 2005
  2. pmc Characterizing the cancer genome in lung adenocarcinoma
    Barbara A Weir
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 450:893-8. 2007
  3. pmc Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays
    Rameen Beroukhim
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    PLoS Comput Biol 2:e41. 2006
  4. doi request reprint DNA sequencing of cancer: what have we learned?
    Juliann Chmielecki
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts 02115 email
    Annu Rev Med 65:63-79. 2014
  5. pmc A novel totivirus and piscine reovirus (PRV) in Atlantic salmon (Salmo salar) with cardiomyopathy syndrome (CMS)
    Marie Løvoll
    Section for Virology and Serology, National Veterinary Institute, P, O, Box 750 Sentrum, 0106 Oslo, Norway
    Virol J 7:309. 2010
  6. pmc GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
    Craig H Mermel
    Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
    Genome Biol 12:R41. 2011
  7. pmc Major copy proportion analysis of tumor samples using SNP arrays
    Cheng Li
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 3 Blackfan Circle, Boston, MA 02115, USA
    BMC Bioinformatics 9:204. 2008
  8. doi request reprint Advances in understanding cancer genomes through second-generation sequencing
    Matthew Meyerson
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Rev Genet 11:685-96. 2010
  9. ncbi request reprint Telomerase enzyme activation and human cell immortalization
    M Meyerson
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Toxicol Lett 102:41-5. 1998
  10. ncbi request reprint Human genetic variation and disease
    Matthew Meyerson
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Lancet 362:259-60. 2003

Detail Information

Publications71

  1. ncbi request reprint Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
    Xiaojun Zhao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:5561-70. 2005
    ..EGFR amplification was shown to be independent of kinase domain mutational status...
  2. pmc Characterizing the cancer genome in lung adenocarcinoma
    Barbara A Weir
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 450:893-8. 2007
    ..More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered...
  3. pmc Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays
    Rameen Beroukhim
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    PLoS Comput Biol 2:e41. 2006
    ..We have developed a method for analyzing high-density oligonucleotide SNP array data to accurately identify of regions of LOH and retention in tumors without the need for paired normal samples...
  4. doi request reprint DNA sequencing of cancer: what have we learned?
    Juliann Chmielecki
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts 02115 email
    Annu Rev Med 65:63-79. 2014
    ..Additionally, genomic sequencing has revealed the complexity of the cancer genome and has enabled the discovery of functional rearrangements with therapeutic and diagnostic potentials. ..
  5. pmc A novel totivirus and piscine reovirus (PRV) in Atlantic salmon (Salmo salar) with cardiomyopathy syndrome (CMS)
    Marie Løvoll
    Section for Virology and Serology, National Veterinary Institute, P, O, Box 750 Sentrum, 0106 Oslo, Norway
    Virol J 7:309. 2010
    ..In the present work we have studied whether PRV or other infectious agents may be involved in the etiology of CMS...
  6. pmc GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
    Craig H Mermel
    Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
    Genome Biol 12:R41. 2011
    ..Here we detail this revised computational approach, GISTIC2.0, and validate its performance in real and simulated datasets...
  7. pmc Major copy proportion analysis of tumor samples using SNP arrays
    Cheng Li
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 3 Blackfan Circle, Boston, MA 02115, USA
    BMC Bioinformatics 9:204. 2008
    ..We have previously used Hidden Markov Models (HMM) to analyze SNP array data for inferring copy numbers and loss-of-heterozygosity (LOH) from paired normal and tumor samples and unpaired tumor samples...
  8. doi request reprint Advances in understanding cancer genomes through second-generation sequencing
    Matthew Meyerson
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Rev Genet 11:685-96. 2010
    ..This Review focuses on the methodological considerations for characterizing somatic genome alterations in cancer and the future prospects for these approaches...
  9. ncbi request reprint Telomerase enzyme activation and human cell immortalization
    M Meyerson
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Toxicol Lett 102:41-5. 1998
    ..In contrast, disruption of the mouse telomerase RNA subunit gene, mTERC, results in a delayed failure of cell proliferation. Telomerase activity therefore appears to be necessary for the prolonged survival of mammalian cells...
  10. ncbi request reprint Human genetic variation and disease
    Matthew Meyerson
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Lancet 362:259-60. 2003
  11. ncbi request reprint Role of telomerase in normal and cancer cells
    M Meyerson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 18:2626-34. 2000
    ..Moreover, data on the experimental use of telomerase assays for cancer detection and diagnosis are reviewed. Finally, the review considers the evidence regarding whether telomerase inhibitors could be used to treat human cancers...
  12. ncbi request reprint Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 66:11389-98. 2006
    ..These studies suggest that cyclin D1 may contribute to the emergence of EGFR-driven tumorigenesis and can be an alternative target of therapy...
  13. pmc Allele-specific amplification in cancer revealed by SNP array analysis
    Thomas LaFramboise
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS Comput Biol 1:e65. 2005
    ..An R software package containing the methods described in this paper is freely available at http://genome.dfci.harvard.edu/~tlaframb/PLASQ...
  14. pmc Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification
    J Guillermo Paez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Nucleic Acids Res 32:e71. 2004
    ..These results suggest that phi29MDA yields high fidelity, near-complete genome representation suitable for high resolution genetic analysis...
  15. pmc Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
    Heidi Greulich
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS Med 2:e313. 2005
    ..The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described...
  16. ncbi request reprint EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..These results suggest that EGFR mutations may predict sensitivity to gefitinib...
  17. ncbi request reprint High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 23:2716-26. 2004
    ..Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels...
  18. pmc Activating mutations in ALK provide a therapeutic target in neuroblastoma
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 455:975-8. 2008
    ....
  19. ncbi request reprint Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  20. ncbi request reprint Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP
    Marshall E Lieberfarb
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:4781-5. 2003
    ..This organizational strategy revealed apparently distinct genetic subsets of prostate cancer...
  21. ncbi request reprint An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays
    Xiaojun Zhao
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 64:3060-71. 2004
    ..The simultaneous measurement of DNA copy number changes and loss of heterozygosity events by SNP arrays should strengthen our ability to discover cancer-causing genes and to refine cancer diagnosis...
  22. ncbi request reprint Cancer genomes evolve by pulverizing single chromosomes
    Matthew Meyerson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115 Department of Pathology, Harvard Medical School, Boston, MA 02115 Broad Institute, Cambridge, MA 02142
    Cell 144:9-10. 2011
    ..Chromothripsis appears to be a cataclysmic event in which a single chromosome is fragmented and then reassembled. The phenomenon raises important questions of how chromosome rearrangements can be confined to defined genome segments...
  23. doi request reprint Modeling genomic diversity and tumor dependency in malignant melanoma
    William M Lin
    Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 68:664-73. 2008
    ..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors...
  24. ncbi request reprint Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    Yuki Yuza
    Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Biol Ther 6:661-7. 2007
    ..More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target...
  25. ncbi request reprint A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:751-8. 2006
    ..Here we describe the use of a sensitive screening method that overcomes many of these limitations...
  26. ncbi request reprint EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    ..Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance...
  27. pmc Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    David A Barbie
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115 USA
    Nature 462:108-12. 2009
    ..These observations indicate that TBK1 and NF-kappaB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer...
  28. ncbi request reprint LKB1 modulates lung cancer differentiation and metastasis
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 448:807-10. 2007
    ..These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis...
  29. ncbi request reprint Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types
    Ian Krop
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
    Mol Cancer Res 2:489-94. 2004
    ..Thus, silencing of HIN-1 expression and methylation of its promoter occurs in multiple human cancer types, suggesting that elimination of HIN-1 function may contribute to several forms of epithelial tumorigenesis...
  30. ncbi request reprint PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    ..These preclinical evaluations support further clinical development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members...
  31. ncbi request reprint Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Mohamed Bentires-Alj
    Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer Res 64:8816-20. 2004
    ..Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy...
  32. ncbi request reprint Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:760-6. 2007
    ..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement...
  33. ncbi request reprint Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers
    Zhigang C Wang
    Departments of Surgery and Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Res 64:64-71. 2004
    ..Furthermore, exclusive association between biological subclasses and restricted LOH events provides rationale to search for targeted genes...
  34. pmc Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
    Takeshi Shimamura
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 68:5827-38. 2008
    ..Nonetheless, these findings suggest that Hsp90 inhibitors may be effective in T790M-expressing cells and offer an alternative therapeutic strategy for this subset of lung cancers...
  35. pmc Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays
    Rani E George
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 2:e255. 2007
    ..We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy number change using the Affymetrix 10K single nucleotide polymorphism (SNP) array...
  36. ncbi request reprint Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
    Jingrui Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:8968-74. 2005
    ..Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacologic EGFR inhibition on the distinct mutant forms of this tyrosine kinase...
  37. ncbi request reprint Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
    Sean Tracy
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 64:7241-4. 2004
    ..These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib...
  38. pmc Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:7817-22. 2006
    ..These findings suggest a therapeutic strategy for cancers harboring the EGFRvIII mutation...
  39. pmc Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney
    Rameen Beroukhim
    Departments of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 69:4674-81. 2009
    ....
  40. ncbi request reprint Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    Takeshi Shimamura
    Department of Medical Oncology and Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 66:6487-91. 2006
    ..Thus, the subset of NSCLC patients with tumors carrying the ERBB2 G776insV_G/C mutation may benefit from treatment with HKI-272...
  41. ncbi request reprint Telomerase activation, cellular immortalization and cancer
    W C Hahn
    Department of Adult Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Med 33:123-9. 2001
    ..These applications include inhibiting or targeting telomerase as a novel antineoplastic strategy and using cells immortalized by telomerase for therapeutic applications...
  42. pmc CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity
    Ron Firestein
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 455:547-51. 2008
    ..Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in beta-catenin-driven malignancies...
  43. pmc Amplification of chromosomal segment 4q12 in non-small cell lung cancer
    Alex H Ramos
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA, USA
    Cancer Biol Ther 8:2042-50. 2009
    ..Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors...
  44. ncbi request reprint SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients
    Kenneth D Swanson
    Cancer Biology Program, Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA
    Genes Chromosomes Cancer 47:253-9. 2008
    ..Our findings suggest that SOS1 is not a significant human oncogene in most cancers. Furthermore, NS patients with SOS1 mutations may not be at increased risk of developing cancer...
  45. pmc Lin28 promotes transformation and is associated with advanced human malignancies
    Srinivas R Viswanathan
    Children s Hospital Boston, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA, USA
    Nat Genet 41:843-8. 2009
    ..Our work provides a mechanism for the coordinate repression of let-7 miRNAs observed in a subset of human cancers, and associates activation of LIN28 and LIN28B with poor clinical prognosis...
  46. pmc Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
    Derek Y Chiang
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:6779-88. 2008
    ..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies...
  47. ncbi request reprint Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 66:3162-8. 2006
    ..Thus, STAT3 is a critical mediator of the oncogenic effects of somatic EGFR mutations and targeting STAT3 may be an effective strategy for treating tumors characterized by these mutations...
  48. ncbi request reprint Integrative genomic approaches identify IKBKE as a breast cancer oncogene
    Jesse S Boehm
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cell 129:1065-79. 2007
    ..These observations suggest a mechanism for NF-kappaB activation in breast cancer, implicate the NF-kappaB pathway as a downstream mediator of PI3K, and provide a framework for integrated genomic approaches in oncogene discovery...
  49. ncbi request reprint Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School Partners Healthcare Center for Genetics and Genomics, MGH Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Oncologist 12:90-8. 2007
    ..6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information...
  50. ncbi request reprint Genomic approaches to lung cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 12:4384s-4391s. 2006
    ..Taken together, the application of genomics technologies has led to important discoveries with clinical implications in lung cancer that might help to improve clinical care for patients suffering from this highly fatal tumor...
  51. pmc Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity
    Cai Hong Yun
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA 02115, USA
    Cancer Cell 11:217-27. 2007
    ..Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme...
  52. pmc TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity
    M C Liang
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Oncogene 29:1588-97. 2010
    ..Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited...
  53. pmc Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments
    Torstein Tengs
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Nucleic Acids Res 32:e121. 2004
    ..Here, we show that the RECORD libraries may be used for digital karyotyping and for pathogen identification by computational subtraction...
  54. ncbi request reprint Missense mutations of the BRAF gene in human lung adenocarcinoma
    Katsuhiko Naoki
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 62:7001-3. 2002
    ..These specimens belong to the same adenocarcinoma subgroup as defined by clustering of gene expression data. BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients...
  55. ncbi request reprint Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Ross L Levine
    Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 7:387-97. 2005
    ..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase...
  56. pmc EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    Jussi P Koivunen
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D820A, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 14:4275-83. 2008
    ..We determined the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines. We also determined whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-containing cell lines in vitro and in vivo...
  57. ncbi request reprint Molecular classification and molecular genetics of human lung cancers
    Matthew Meyerson
    Department of Medical Oncology, Dana Farber Cancer Insitute, Boston, MA 02115, USA
    Semin Oncol 31:4-19. 2004
    ..These data may be useful in tailoring chemotherapeutic protocols to individual tumors and identifying new targets for therapeutic intervention...
  58. pmc The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor
    Susanne Schlisio
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 22:884-93. 2008
    ....
  59. ncbi request reprint TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115 6110, USA
    Cancer Res 66:8337-41. 2006
    ..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement...
  60. ncbi request reprint High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  61. ncbi request reprint Identification of foreign gene sequences by transcript filtering against the human genome
    Griffin Weber
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 30:141-2. 2002
    ..We demonstrate the potential of this method by identifying sequences from known pathogens in established expressed-sequence tag libraries...
  62. pmc The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
    Cai Hong Yun
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:2070-5. 2008
    ....
  63. pmc A structure-guided approach to creating covalent FGFR inhibitors
    Wenjun Zhou
    Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Chem Biol 17:285-95. 2010
    ..FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases...
  64. ncbi request reprint Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Med 12:852-5. 2006
    ..This technology can thereby facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies...
  65. ncbi request reprint Somatic alterations in the human cancer genome
    Barbara Weir
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Cancer Cell 6:433-8. 2004
    ..With further development of targeted cancer therapies and improvement in genome analysis technology, genome-wide surveys of cancer will likely become tools for diagnosis as well as discovery...
  66. pmc Drug-sensitive FGFR2 mutations in endometrial carcinoma
    Amit Dutt
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:8713-7. 2008
    ..Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma...
  67. pmc HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
    Samanthi A Perera
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:474-9. 2009
    ..Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted...
  68. ncbi request reprint Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583
    Laura E MacConaill
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Mol Cancer Res 4:793-801. 2006
    ..Chromatin immunoprecipitation experiments reveal that binding of menin to the Hoxc8 locus is not affected by phosphorylation on Ser543 or Ser583...
  69. pmc BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008
    ..These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes...
  70. ncbi request reprint Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
    Jingrui Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D720C, Boston, MA 02115, USA
    Blood 104:1855-8. 2004
    ..These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412...
  71. ncbi request reprint Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
    ..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression...

Research Grants16

  1. Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma
    Matthew L Meyerson; Fiscal Year: 2010
    ..Specific Aim 4. Determine whether cancer-derived point mutations in the extracellular domain of EGFR are transforming and whether these mutants can be inhibited by small molecule kinase inhibitors. ..
  2. Center for Cancer Genome Characterization
    Matthew Meyerson; Fiscal Year: 2007
    ..3) Cross-validate, integrate, and analyze CGCC data to determine regions of genome alteration for high-throughput sequencing. (4) Rapidly share data with the cancer research community. ..
  3. Elucidating the somatic genetics of prostate cancer
    Matthew Meyerson; Fiscal Year: 2007
    ..4. To begin the functional validation of selected candidate tumor suppressor and oncogenes identified in aims 1 through 3. ..
  4. Inhibitor-sensitive and -resistant EGFR mutants from lung cancer and glioblastoma
    Matthew Meyerson; Fiscal Year: 2007
    ..Specific Aim 4. Determine whether cancer-derived point mutations in the extracellular domain of EGFR are transforming and whether these mutants can be inhibited by small molecule kinase inhibitors. ..
  5. Cancer Virus Discovery by Computational Subtraction
    Matthew Meyerson; Fiscal Year: 2005
    ..These include auto-immune diseases and inflammatory diseases, as well as uncharacterized epidemics, whether natural or bio-terrorist in origin. ..
  6. NKX2-1, A Candidate Lineage Survival Oncogene in Lung Adenocarcinoma
    Matthew L Meyerson; Fiscal Year: 2010
    ..Our hope is that this understanding will lead to improved diagnosis and treatment of lung adenocarcinoma. ..